COMMUNIQUÉS West-GlobeNewswire

A.D.A.M. Innovations Unveils GeneLock™: The World’s First Genetic Data Protection Platform
24/04/2026
Pioneering Biosecurity for Genomic Data TOKYO, April 24, 2026 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.) today announced GeneLock™, a new genomic security platform [...]
Acentra Health Chief AI Officer Sean Harrison Named to NVTC AI50
24/04/2026
Inaugural Award Highlights Executive and Company Dedication to AI Innovation in Northern Virginia Region MCLEAN, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions company [...]
Dogecoin Cash, Inc. Highlights Telehealth Platform Strategy Following Federal Actions Relating to Marijuana Reclassification
24/04/2026
Majority-owned PrestoDoctor platform operates within state-regulated medical cannabis frameworks as federal classification evolves Mesquite, NV, April 24, 2026 (GLOBE NEWSWIRE) -- Mesquite, Nevada - Dogecoin Cash, Inc [...]
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
24/04/2026
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, [...]
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
24/04/2026
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first [...]
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
24/04/2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
24/04/2026
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European Union Itvisma demonstrated [...]
Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System
24/04/2026
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from the previously [...]
Free Carotenoid Eye Screenings Offered to Seacoast Residents Near Portsmouth, NH
24/04/2026
Fox Run Eye Care launches free carotenoid screenings for Seacoast families — and brings 25 years of patient-first optometry to a stunning new vision center in Greenland, NH GREENLAND, N.H., April 24, 2026 (GLOBE [...]
30 Years of Smiles: St. Augustine’s Premier Cosmetic Dentist Marks a Career Built on Artistry
24/04/2026
Dr. Atosa Khan celebrates three decades of dental excellence and 20 years of independent practice at one of Northeast Florida’s most distinguished dental offices ST. AUGUSTINE, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- [...]
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
24/04/2026
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which demonstrated that [...]
Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées
24/04/2026
Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées [...]
Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis
24/04/2026
SANDWICH, United Kingdom, April 24, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive [...]
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Geneva College of Longevity Science Launches the World’s First PhD in Longevity Sciences
24/04/2026
GENEVA and CONSTANȚA, Romania, April 24, 2026 (GLOBE NEWSWIRE) -- The Geneva College of Longevity Science (GCLS) today announced the launch of the world’s first PhD in Medicine with a specialization in Longevity [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
The top 250 cancer specialists converge in Belgium to push the frontiers of proton therapy
24/04/2026
IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]

Pages